The RSV Vaccine Study (Brisbane)
The study drug is a potential new vaccine against rRSV (recombinant Respiratory Syncytial Virus).
This virus is the leading cause of severe lower respiratory tract disease in children, the elderly population, and immunosuppressed people.
It is estimated that more than 60% of all acute respiratory infections in children worldwide are caused by RSV. Adults over the age of 65 are also 6.6 times more likely to be hospitalised due to RSV infections. While there is a great need for an RSV vaccine for different populations, there is currently no approved RSV vaccine available.
**For this study participants must not have previously received a vaccination with any licensed or investigational RSV vaccine.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!